LIMITED CONSENT AND FIRST AMENDMENT TO CREDIT AGREEMENTCredit Agreement • November 7th, 2022 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This LIMITED CONSENT AND FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of October 28, 2022 (this “Amendment”), to that certain Credit Agreement dated as of May 11, 2021 (as amended, modified and restated from time to time prior to the date hereof, the “Existing Credit Agreement” and, the Existing Credit Agreement, as amended by this Amendment, the “Credit Agreement”), by and among MARINUS PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), certain Subsidiaries of the Borrower that may be required to provide Guarantees from time to time thereunder (each a “Guarantor” and collectively, the “Guarantors”), the lenders from time to time thereunder (each a “Lender” and collectively, the “Lenders”), and OAKTREE FUND ADMINISTRATION, LLC, as administrative agent for the Lenders (in such capacity, the “Administrative Agent”) is entered into by and among the Borrower, the Administrative Agent and the undersigned Lenders (collectively, the “Parties”).
REVENUE INTEREST FINANCING AGREEMENT by and between MARINUS PHARMACEUTICALS, INC., as the Company, and SAGARD HEALTHCARE ROYALTY PARTNERS, LP, as the Investor Dated October 28, 2022Revenue Interest Financing Agreement • November 7th, 2022 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This REVENUE INTEREST FINANCING AGREEMENT (this “Agreement”) dated as of October 28, 2022 is by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Royalty Partners, LP, a Cayman Islands exempted limited partnership (the “Investor”). Each of the Company and the Investor are referred to in this Agreement as a “Party” and collectively as the “Parties”.
SECURITY AGREEMENTSecurity Agreement • November 7th, 2022 • Marinus Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
THIS SECURITY AGREEMENT (this “Agreement”), dated as of October 28, 2022, is made by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Company’s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section 24 (each a “Subsidiary Guarantor” and, together with the Company, each a “Grantor” and, collectively, the “Grantors”), and Sagard Healthcare Royalty Partners, LP, as the Investor under the Revenue Interest Financing Agreement referred to below (in such capacity, together with its successors and assigns, the “Investor”).
